{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-128613","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.803480+00:00","generated_at":"2026-06-21T02:14:31.775318+00:00","sec_items":["1.01","1.02","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Regeneron enters into new $750M revolving credit facility, replaces prior facility","bullets":["New $750M senior unsecured five-year revolving credit facility maturing Dec 19, 2027.","Interest rate variable: SOFR or alternate base rate plus margin tied to debt rating and leverage ratio.","Includes $500M accordion to increase commitments or add term loans with lender consent.","ESG amendment option to adjust pricing based on environmental, social, governance targets.","No borrowings outstanding at closing; prior $750M facility terminated simultaneously."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-128613","json":"https://secwatch.observer/filing/0001104659-22-128613.json","markdown":"https://secwatch.observer/filing/0001104659-22-128613.md","text":"https://secwatch.observer/filing/0001104659-22-128613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/0001104659-22-128613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/tm2233051d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:14:31.775318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05ff778e069d3ff8f79dc0fcf0c4a4e48ff14288","claim":"REGENERON PHARMACEUTICALS, INC. incurred revolving credit of $750 million with JPMorgan Chase Bank, N.A. at variable interest rate based on SOFR or alternate base rate plus applicable marg maturing December 19, 2027.","evidence_excerpt":"The Credit Agreement provides for a $750 million senior unsecured five-year revolving credit facility (with a $25 million sublimit for swingline borrowings and a $50 million sublimit for letters of credit)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/0001104659-22-128613-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"$750 million"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Rate","value":"variable interest rate based on SOFR or alternate base rate plus applicable marg"},{"label":"Maturity","value":"December 19, 2027"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"b4c9df69342a2f4298ede6205477ef2c1aff0590","claim":"REGENERON PHARMACEUTICALS, INC. terminated Prior Credit Agreement with JPMorgan Chase Bank, N.A. valued at Prior $750 million revolving credit facility terminated (effective 2022-12-19).","evidence_excerpt":"On the Closing Date, in connection with the entry into the Credit Agreement as described in Item 1.01 above, the Company terminated its then-existing credit agreement, dated as of December 14, 2018, as amended prior to the Closing Date (the “ Prior Credit Agreement ”), by and among Regeneron, as a borrower and guarantor; certain subsidiaries of Regeneron party thereto as subsidiary borrowers; the lenders and issuing banks from time to time party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/0001104659-22-128613-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Value","value":"Prior $750 million revolving credit facility terminated"},{"label":"Effective","value":"2022-12-19"}],"fact_type":"material_agreement"},{"claim_id":"ed43b04d3ff1f482402b2fd8babf84bfd05a1417","claim":"REGENERON PHARMACEUTICALS, INC. entered into Credit Agreement with JPMorgan Chase Bank, N.A. valued at $750 million senior unsecured five-year revolving credit facility (effective 2022-12-19).","evidence_excerpt":"On December 19, 2022 (the “ Closing Date ”), Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) entered into a credit agreement (the “ Credit Agreement ”) by and among the Company, as a borrower and guarantor; certain direct subsidiaries of the Company, as the initial subsidiary borrowers; the lenders and issuing banks from time to time party thereto; and JPMorgan Chase Bank, N.A., as administrative agent, swingline lender, and an issuing bank. The Credit Agreement provides for a $750 million senior unsecured five-year revolving credit facility","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465922128613/0001104659-22-128613-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Value","value":"$750 million senior unsecured five-year revolving credit facility"},{"label":"Effective","value":"2022-12-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}